Salesforce recently pulled back the curtain on a plan to adapt its customer management and analytics software specifically for the use of life sciences companies, and several supporting roles in that production are now taking shape.
According to an announcement this week, consulting giant Accenture will add its own expertise both in the biomedical research industry and in artificial intelligence technologies to the Salesforce Life Sciences Cloud to help fulfill the new software’s mission of making medtech, biotech and pharma companies more efficient.
The collaboration will build on Accenture and Salesforce’s existing partnership in the field of AI, which kicked off earlier this year with plans to build an “acceleration hub” that would help companies take advantage of the generative AI technology available through Salesforce’s signature customer relationship management (CRM) platform.
“Accenture’s deep understanding of the pharma and medtech spaces and their current work to transform patient experiences will help us create new innovation for life sciences companies and in the new development of Salesforce Life Sciences Cloud,” Amit Khanna, senior vice president and general manager of health and life sciences at Salesforce, said in the announcement.
Sourced from FierceBiotech